0Z
0Z2.F Alector Inc
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2023.
Is 0Z2.F undervalued?
Graham numberThe Graham number of Alector Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Alector Inc fundamental analysis
No fundamental analysis for Alector Inc yet.
Alector Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Alector Inc
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical devel…
Full company profileAlector Inc financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Alector Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|---|---|
| Cash Flow | |||||||
| Operating Cash Flow | -17.8M | 127M | -99.3M | -167M | 299M | -20.3M | - |
| Capital Expenditure | 801K | 1.88M | 15.3M | 5.03M | 3.25M | 4.12M | 0.00 |
What these items mean
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
Alector Inc dividends
Alector Inc has not paid dividends in the last 8 fiscal years.
Who owns Alector Inc
- Insiders 7.35%
- Institutions 82.85%
- Public & others 9.80%
- Free float 102M
Alector Inc company profile
- Company name
- Alector Inc
- Ticker
- 0Z2.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Oil, Gas & Consumable Fuels
- Employees
- 103
- Fiscal year end
- December
- Address
- 131 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
- Phone
- 415 231 5660
- Website
- alector.com
About Alector Inc
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.
Alector Inc management
9- Dr. Arnon Rosenthal Ph.D.Co-Founder, CEO & Director · born 1956
- Mr. Neil Berkley M.B.A., M.S.CFO & Chief Business Officer · born 1974
- Ms. Grace Wong-SaradChief Accounting Officer & Principal Accounting Officer
- Ms. Katie HoganSenior Director of Corporate Communication & Investor Relations
- Ms. Danielle Pasqualone J.D., Ph.D.General Counsel
- Ms. Clare Hunt M.B.A.Chief People & Places Officer
- Dr. Hua Long DABT, Ph.D.Senior VP & Head of Research
- Dr. Caiyan Li Ph.D.Head of Clinical Development & Data Science
- Dr. Eric Brown Ph.D.Director of Antibody Discovery & Protein Engineering